AAIC 2026 findings show primary-care doctors using PrecivityAD2 blood results reached almost specialist-level accuracy, and regulators later cleared that test for symptomatic adults age 40 and older. For younger-onset families, the comparison turns on age cutoff, care setting, and whether symptoms are already present.
An Alzheimer's blood test measures disease proteins in blood, here amyloid-beta plus phosphorylated tau. It does not replace a clinical exam. It gives the doctor biological evidence to interpret alongside history, thinking tests, and other causes.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the primary-care study find?
- Why does the age-40 clearance matter?
- How do the current test options compare?
- What should families do before asking for testing?
What did the primary-care study find?
In a Swedish real-world study of 1,310 patients with mild cognitive impairment or dementia, primary-care accuracy rose from 65% to 93% after disclosure of PrecivityAD2 results, the Alzheimer's Association reports in its study summary. Mild cognitive impairment means noticeable thinking changes that do not yet block daily life. After seeing blood results, primary-care physicians scored 93% and dementia specialists scored 94%.
That result effectively closed the usual gap between clinic types. The same study found physicians changed diagnosis in about one-third of cases and changed management plans in over half. Amyloid-beta is a plaque protein linked to Alzheimer's. Phosphorylated tau is a modified tau protein tied to tangles.
Why does the age-40 clearance matter?
On Aug. 20, 2026, FDA cleared C2N Diagnostics' PrecivityAD2 for symptomatic adults age 40 and older, according to C2N Diagnostics in its FDA clearance notice. That made it the first Alzheimer's blood test cleared below age 55.
The age cutoff matters because younger-onset symptoms often start in the 40s or early 50s. Families in that group were previously outside the labeled age range for other tests. Clearance still requires symptoms and clinician supervision. It does not approve testing based only on family history or worry.
How do the current test options compare?
Earlier clearances cover different ages and uses, the BrightFocus Foundation explains in its test comparison guide. Age and setting therefore limit direct comparison.
A family comparing labels should match birth age, symptom status, and ordering clinic to the label. A 48-year-old with memory symptoms fits a different option than a 68-year-old in specialty care.
- Fujirebio Lumipulse p-tau217/Aβ42 ratio: cleared May 2025, ages 55 and older, specialty care.
- Roche Elecsys pTau181: cleared Oct. 2025, primary-care rule-out use.
- C2N PrecivityAD2: cleared Aug. 2026, symptomatic adults age 40 and older.
What should families do before asking for testing?
Current Alzheimer's Association guidance restricts blood-biomarker testing to symptomatic patients under clinician supervision, not general screening. The guidance also recommends at least 90% sensitivity and specificity to replace PET scans or spinal fluid.
A separate AAIC 2026 study of nearly 2,700 cognitively healthy older adults linked very high plasma p-tau217 to later impairment risk. That work supports prognosis in asymptomatic people, not current diagnosis. Ask the primary-care doctor for referral if symptoms began before age 55 and persist.
- Track symptoms, onset age, daily impact, and other medical causes.
- Bring medication lists, sleep, mood, hearing, and thyroid history.
- Ask whether the clinic uses the test for diagnosis or rule-out.
- Ask what follow-up is planned for positive, unclear, or negative results.
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What Primary Care Patients Should Know About the News
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What Is Established and What Remains Uncertain for Younger-Onset Alzheimer’s Families
- The NIA 2026 Dementia Care and Caregiving Summit Report: What Changed and What Comes Next for Spouses and Partners
